Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on LinkedIn:
“Thanks to my colleagues in China for a very engaging discussion on TROP2 ADCs in NSCLC – a massive audience with thoughtful questions. When and where can we incorporate these agents? How do we position these vs amivantamab or AK112 (ivonescimab)? Best partners? Biomarkers?”
